Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs. Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients. We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies. We are guided by our conviction in people, products and breakthrough ideas, not by conventional categories. Our investments span a variety of instruments from early venture rounds, to late-stage investing, direct secondary transactions, as well as company founding and creation. Omega Funds has raised more than $1 billion since its inception in 2004 and is headquartered in Boston, Massachusetts, USA.